Shares of Abivax surged by more than 38% on June 30, 2026 after new Phase 3 data eased safety concerns about cancer, causing the French biotech company's value to drop by up to 43% in early June

The stock price rebound this time is a continuation of the latest results from obefazimod, a leading treatment for ulcerative colitis developed by Abivax. The data shows long-term symptom relief with no new safety risks.

A reversal in safety signals.

Abivax shares fell 43% on June 2 after preliminary trial data showed an increase in cancer rates in patients using obefazimod.

The company disclosed new Phase 3 data on Sunday, June 28, covering patients who failed initial treatment. Researchers found that the incidence of cancer was within the range doctors typically observe in patients with ulcerative colitis. This update helps ease safety concerns, which were the reason the stock fell on June 2.

Among patients who failed initial treatment, 37.2% achieved clinical remission, and 34.5% achieved endoscopic remission by week 44. These results reinforce the drug’s efficacy in harder-to-treat patient groups.

Abivax shares are currently up more than 1,730% over the past year.

Wall Street is split on the issue of risk.

Analysts are divided on how much residual risk remains. Citizens has raised its price target for Abivax shares to 187 USD and maintained an Outperform rating, highlighting the benefits of the drug for symptom relief compared with placebo.

Wedbush is more cautious. It upgraded its rating for Abivax shares from Underperform to Neutral, but cut its price target to 90 USD. Wedbush points to lingering doubts about cancer in the 50 mg dosage group as a licensing-related risk.

Abivax continues to plan to file for drug approval with the FDA in the fourth quarter of 2026. Until then, the stock will remain sensitive to additional safety-related information.